GlassScriptPhysician profile
David A Diaz
NPI 1033106380
$1,866.86
in general payments reported to CMS, 2019-2025
20 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $400 · 2021: $323 · 2022: $153 · 2023: $395 · 2024: $241 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.75 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $267.56 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $189.89 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $184.36 | 2019-2021 | |
| Novo Nordisk INC | $172.91 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $113.60 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $85.23 | 2021-2023 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $73.74 | 2023 | Quviviq |
| Exact Sciences Corporation | $70.97 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $54.03 | 2020-2021 | |
| Inspire Medical Systems, INC. | $52.57 | 2023 | Inspire |
| Allergan, INC. | $49.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.16 | 2020-2021 | |
| Eisai INC. | $28.79 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $27.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.90 | 2023 | |
| Amgen INC. | $23.71 | 2025 | Repatha |
| Boston Scientific Corporation | $18.42 | 2022 | |
| Abbott Laboratories | $18.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.